The Humoral Immune landscape of Chronic Lymphocytic Leukemia: biological implications and clinical impact
Pablo Juanes-Velasco
Centro de Investigación del Cáncer. Universidad de Salamanca - CSIC
The molecular heterogeneity of Chronic Lymphocytic Leukemia (CLL) poses significant challenges in understanding immune dysregulation and patient-specific disease progression. Current studies suggest that CLL cells exhibit altered humoral immunity, which may have implications for patient stratification and treatment decisions. Using
deep proteomics profiling in 276 CLLs from discovery and validation cohorts, we identified both dysregulated protein profiles involved in intracellular signaling pathways,
and individual proteins with prognostic impact. This proteomic data provides fresh insights into the molecular landscape of CLL, highlighting novel biomarkers and potential therapeutic targets in overall disease evolution and in TP53 mutated patients.
Our findings underscore the value of implementing proteomic approaches to refine the molecular basis of CLL and enhance patient care strategies.